Jonah Feldman

Findings from a phase 1 trial evaluating CAR T-cell therapy in patients with solid tumors showed promising clinical benefit with the treatment strategy.

Patients with hepatocellular carcinoma experienced better health-related quality of life outcomes with tislelizumab vs sorafenib.

A study presented at the 2023 San Antonio Breast Cancer Symposium showcased real-world outcomes with trastuzumab deruxtecan (T-DXd; Enhertu) in patients with advanced breast cancer (aBC) whose HER2 expression status switched during treatment. In 191 real-world patients with HER2-positive (HER2+), HER2-low, and HER2-0 status, the median time to next treatment (TTNT) after T-DXd was 10.4 months, 7.6 months, and 3.7 months, respectively, at 10.4 months median follow-up (P < .001). Patients whose…

A post hoc sensitivity analysis that counted use of subsequent therapies in patients censored from primary overall survival follow-up favored darolutamide plus androgen deprivation therapy and docetaxel in patients with metastatic hormone-sensitive prostate cancer.

Sacituzumab govitecan (SG; Trodelvy) produced “limited efficacy” for patients with metastatic urothelial carcinoma (mUC) previously treated with enfortumab vedotin (EV; Padcev), according to a single-center retrospective study presented in a poster at the 2024 ASCO Annual Meeting.1 There was an objective response rate (ORR) of 11% (95% CI, 5.2-20) and a median progression-free survival (PFS) of 2.1 months (95% CI, 1.9-2.5) in 82 patients who received EV before SG. The efficacy was not as favo…

T-DXd Outranks Treatment of Physicians’ Choice in QOL for HR+/HER2-Low/Ultralow MBC

Following risk management measures, ponatinib-associated adverse events in CML and ALL were shown to have decreased significantly since the drug’s approval.

Patients treated with ide-cel, Abecma for relapsed/refractory multiple myeloma affecting the central nervous system had similar outcomes to matched patients with non-CNS multiple myeloma.